On Wednesday, Following Stocks were among the “Top Losers” In U.S. Stock Exchange: Wright Medical Group (NASDAQ:WMGI), Oncothyreon (NASDAQ:ONTY), Immunomedics, (NASDAQ:IMMU), Regions Financial (NYSE:RF)
Wright Medical Group Inc (NASDAQ:WMGI) stated financial results for its fourth quarter and full-year ended December 31, 2014 and offered 2015 guidance. As a result of the accomplished sale of the hip and knee business to MicroPort Medical B.V., a partner of MicroPort Scientific Corporation (MicroPort), this business is stated as suspended operations.
Net sales totaled $83.3 million during the fourth quarter ended December 31, 2014, representing a 23% raise as stated and 25% raise on a constant currency basis contrast to the fourth quarter of 2013.
Wright Medical Group Inc (NASDAQ:WMGI)’s shares picked down -2.30%, and closed at $26.32. The stock volatility for the week is 2.33%, while for the month remained 2.72%. The company holds consensus target price of $30.70.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -4.80 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 22.00% and Annual EPS growth for the past 5 years is considered as -44.25%.
The mean recommendation of analysts for this stock is 2.20. (Where 1=Buy, 5=Sale).
Wright Medical Group Inc (WMGI) a specialty orthopaedic corporation provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients lifestyles worldwide.
Oncothyreon Inc (USA) (NASDAQ:ONTY) stated financial results for the year and quarter ended December 31, 2014. Net loss for the year ended December 31, 2014 was $50.0 million, or $0.64 per basic and diluted share, contrast with a net loss of $38.8 million, or $0.62 per basic and diluted share, for the comparable period in 2013. The rise in net loss was due to higher research and development expenses, primarily as a result of a raise of $10.0 million in license fees paid to Array. The rise in net loss was also the result of higher general and administrative expenses and lower non-cash revenue from the change in fair value of warrant liability, which was $0.8 million for the year ended December 31, 2014 contrast to $2.3 million for the year ended December 31, 2013.
Oncothyreon Inc (USA) (NASDAQ:ONTY) decreased -2.20%, and closed at $1.78.Price to book ratio is 1.78. With recent decline, the year-to-date (YTD) performance reflected a -8.25% decline below last year. During the past month the stock gained 13.38%, bringing three-month performance to -2.73% and six-month performance to -17.21%. The mean recommendation of analysts for this stock is 2.00 (where 1=Buy, 5=Sale).
Oncothyreon Inc (USA) (ONTY) a clinical-stage biopharmaceutical corporation develops therapeutic products for the treatment of cancer. Its product candidate comprises Tecemotide, a vaccine for the treatment of non-small cell lung cancer.
Immunomedics, Inc. (NASDAQ:IMMU) uncovered that 33% of patients with small cell lung cancer (SCLC) and 31% with non-small cell lung cancer (NSCLC) had their tumor reduced in size by 30% or more, after being treated with sacituzumab govitecan, the Corporation’s lead investigational antibody-drug conjugate (ADC). Counting patients that stated stable disease as their best response, the ADC controls the progression of the cancer in 75% and 56% of NSCLC and SCLC patients, respectively. These patients had either failed to respond to their last lung cancer therapies or their cancer had returned or progressed.
Immunomedics, Inc. (NASDAQ:IMMU) decreased -2.17%, and closed at $4.05. The company holds the market capitalization of $386.62M. For the last twelve months, the stock was able to keep return on equity at -174.90%, while return on assets at -130.90%, in response to its return on investment at -90.60%. Its 20-day moving average decreased -1.41%, below 50-day moving average of -8.33%, below 200-day moving average of 5.10% from the latest market price of $4.05. The mean recommendation of analysts for this stock is 1.30. (Where 1=Buy, 5=Sale).
Immunomedics, Inc. (IMMU) a biopharmaceutical corporation, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States.
Regions Financial Corp (NYSE:RF) has been recognized by Greenwich Associates for providing distinguished quality service to small business and middle market clients. Regions Bank received 28 Greenwich Excellence Awards in 2014, the highest number of awards received by any participating bank across the combined Small Business Banking and Middle Market Banking awards categories.
Regions Financial Corp (NYSE:RF) fell 2.02%, and closed at $9.69. The stock has the beta value of 2.12, and its volatility for the week is 2.37%, while for the month it is 1.86%. The company has the market capitalization of $13.28 billion. The company holds the book value per share of 11.79, whereas cash per share is 3.06. Price to book ratio remained 0.82, while price to sale ratio is 3.63. Analysts mean recommendation for the stock is said to be 2.30 (where 1=Buy, 5=sale).
Regions Financial Corp (RF) along with its subsidiaries provides banking and bank-related services to individual and corporate customers in the United States. Its Corporate Bank segment offers commercial banking services, such as commercial and industrial, commercial real estate, and investor real estate lending, in addition to equipment lease financing services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
